Financial Daily from THE HINDU group of publications
Thursday, Feb 21, 2002

News
Features
Stocks
Port Info
Archives

Group Sites

Corporate - Performance


Alembic's new drugs to account for 12% turnover

Our Bureau

NEW DELHI, Feb. 20

THE Baroda-based Alembic Ltd, as part of its shift from acute diseases to chronic disease management, has lined up new drugs in diabetes, cardiac and nutraceuticals segments.

Ms Malika C. Amin, Wholetime Director, told mediapersons that its new product portfolio would account for 12 per cent of its turnover.

Currently, about 36 per cent of its total turnover of Rs 498 crore comes from domestic formulations.

She was briefing the media following the launch of Isovon, a nutraceutical drug for the treatment of premenopausal and menopausal symptoms.

With the launch of Isovon, the company was consolidating its basket of nutraceuticals.

Alembic has entered into a tie-up with the US-based Cognis Health and Nutrition for the import of soy isoflavones.

Priced at Rs 10 per capsule, Isovon comes in a pack of 10.

Send this article to Friends by E-Mail

Stories in this Section
Cadila not to take IPO dose till 2005


Madhusudan cancels EGM -- 51 pc stake sale to Duravit hangs fire
SWC has no plans to offload stake in beer, liquor business
ICAI standards for joint ventures
NJMC petition against tribunal award rejected
Tata Engg writes off Rs 1,180 cr
ABB net up at Rs 65 cr; to pay 50 pc dividend
Positive signs seen in M&M revamp move
Canara Bank, LIC to take CDSL stake
Kyndal plans arm for knowhow sale
Six Continent to bolster Indian presence
DCA probing 6 Reliance cos
Alfa Laval in pact with 2 foreign cos for gasohol
Satyam in alliance with Hummingbird
Tata Steel ties up with Nippon Steel
OmegaTech, Vasta in marketing pact
Kale Consultants-IATA pact for `CEO Cockpit'
Richardson & Cruddas revival scheme declared failed -- ICICI to advertise for change in management
MphasiS hopeful of attaining targets
Alembic's new drugs to account for 12% turnover
IBP's Mathur hangs up his boots sans regrets


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line